Novartis’ Pluvicto presents survival benefit for castration-resistant prostate cancer
pharmaphorum
DECEMBER 5, 2022
It has been announced today that Novartis’ Pluvicto (lutetium vipivotide tetraxetan) has shown statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).
Let's personalize your content